Induction of terminal proliferation arrest, senescence, is important for in vivo tumor suppressive function of p53. Moreover, p53 mutant cells are highly resistant to senescence induction by either oncogenic signaling during cellular transformation, or in response to different therapies. Senescence resistance in p53 mutant cells has been mostly attributed to inhibition of p53's checkpoint function in response to senescenceinducing stress signals. Here we review very recent evidence indicating for an alternative explanation for senescence resistance in p53 defective cancer cells: p21-mediated E2F1 expression. We discuss the potential relevance of these findings for senescence-inducing therapies and highlight cyclin dependent kinases (CDKs) and mechanisms downstream of retinoblastoma protein (RB) as prospective pro-senescence therapy targets. In particular we discuss recent findings indicating important role for E2F1-CIP2A feedback loop in causing senescence resistance in p53 compromised cancer cells. We further propose that targeting of E2F1-CIP2A feedback loop could provide a pro-senescence therapy approach that is effective in both p53-and RB-deficient cancer cells, which together constitute the great majority of all cancer cells. Diagnostic evaluation of the described senescence resistance mechanisms in human tumors might also be informative for patient stratification for already existing therapies.
morphological changes, there are several biomarkers that can be used to detect senescent cells in vitro and in vivo. As comprehensively reviewed by Kuilman and colleagues (1), many of these markers are cell and tissue specific and it has been a challenge to identify markers that would reliably indicate for senescence induction in in vivo tissues.
In addition to replicative senescence, another type of senescence can occur in response to different types of stress stimuli, such as DNA damage, oxidative stress and acute expression of oncogenes or inactivation of tumor suppressors (1). Originally, oncogeneinduced senescence (OIS) was identified in mutant oncogenic H-Ras transfected human and mouse fibroblasts (4) . Later OIS and tumor suppressor inactivation-induced senescence have been reported to prevent transformation in the context of several different oncogenes and tumor suppressors in many tissue types both in vitro and in vivo (5) . For example, in a mutant oncogenic KRAS-driven mouse model, multiple senescent markers are expressed in premalignant lung and pancreas tumors, whereas malignant lung and pancreas adenocarcinomas show robust proliferation (6) . These studies clearly indicate that for malignant transformation, cells have to become resistant to both apoptotic cell death and to senescence induction. In humans, oncogenic mutation in BRAF induces senescence in pre-malignant neavi and arrests malignant melanoma progression (7) . Also, senescence has been detected in early stage human prostate cancer lesions, further indicating that senescence is a restrictive phenomenon during human carcinogenesis (8) .
P53 and its downstream effector pathway in senescence regulation
Tumor suppressor p53 is involved in senescence induction by various senescenceinducing stimuli (9) . Consistent with this, ectopic activation of p53 has been shown to inhibit tumor initiation and tumor maintenance by inducing senescence in vivo (10, 11) . In
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Author Manuscript Published OnlineFirst on May 1, 2014; DOI: 10.1158/1078-0432.CCR- fact, most recent studies indicate that even though apoptosis induction is the classical response to acute p53 induction, it may be rather senescence than apoptosis induction that mediates tumor suppressor function of p53 in vivo (12, 13). In the early days, both p53 and its downstream RB activity were identified as limiting factors in human cellular transformation by forcing cells into cellular senescence (14) . This could be explained by findings that upon oncogene-induced signaling, p53 is stabilized leading to activation of p53 downstream pathway, p53-p21-CDK2-RB-E2F1 (Fig.1) (9) . In fact, it has even been demonstrated that p53 activation by a conditional allele in mouse tumors is not sufficient to induce tumor regression in the absence of Ras-driven oncogenic stress (15) .
Whereas activation of wild-type P53 results in senescence induction, genetic p53 inhibition can overcome oncogenic mutant BRaf induced senescence in mouse lung leading to tumor progression (16) . In addition, P53 inactivation has been shown to overcome Pten inactivation induced senescence in mouse prostate leading to cancer progression (8) . Thus far the senescence resistance of p53 defective cancer cells have been attributed to inhibition of p53 checkpoint function in response to OIS. However, an alternative explanation for senescence resistance of p53 mutant cancer cells could be that p53 inactivation actively drives mechanisms of senescence resistance. In this review, we discuss the latter explanation and uncover that common between these p53 inhibitiondriven senescence resistance mechanisms is that they all feed to E2F1 regulation. We further discuss the potential of these mechanisms as pro-senescence therapy targets. p21 mediates p53-induced senescence Because p53 has a well-established role in senescence induction, it is not a surprise that the downstream targets of p53 are important senescence regulators (9) . Activation of P53 results in induction of direct p53 transcriptional target p21, which further inhibits cyclin Author Manuscript Published OnlineFirst on May 1, 2014; DOI: 10.1158/1078-0432.CCR- dependent kinase 2 (CDK2)/cyclin E complex, leading to RB-mediated E2F1 inhibition ( Fig. 1) (17, 18) . In turn, and relevant for the model proposed in this review, p53 inhibition in cancer cells leads to increased p21 expression and consequent activation of E2F1. We do realize that other downstream effectors of p53 than p21 may as well contribute to senescence regulation, but for the clarity of presentation those mechanisms are not discussed here. The critical role for p21 in senescence regulation, even independently of p53, was supported by two recent articles describing p21-dependent programmed senescence during mouse development (2, 3). As a further support to the central role for p21 in senescence, recent publications have demonstrated p21-induced senescence in p53 defective cancer cell lines (17, (19) (20) (21) , and tumors in vivo (22, 23) .
RB-E2F1 as a nodal point of senescence sensitivity regulation in p53 defective cancer cells As mentioned above, CDK2 inhibition mediates senescence signaling from p21 to RB. In support to important role for CDK2 activity in mediating senescence resistance, inhibition of CDK2 was shown to induce senescence in p53-deficient human leukemic tumor cells and in MYC-driven in vitro and in vivo transformation models (24, 25) . Larsson and coworkers further presented evidence that direct MYC phosphorylation by CDK2 was important for senescence evasion (25) . CDK2 phosphorylates tumor suppressor Retinoblastoma protein (RB) resulting in release of transcription factor E2F1 from RB/E2F1 complex ( Fig. 1) (26) . RB protein family proteins, RB (p105), p107 and p130, have overlapping functions in cell cycle control (26) and compensatory and complementary role in senescence regulation (27, 28) . For example, in the absence of functional RB, p107 was shown to primarily mediate irradiation induced senescence in prostate cancer cells (29) . On the other hand, the most recent data with human fibroblasts shows that RB, but not p107 or p130, has an essential role in oncogene-induced Author Manuscript Published OnlineFirst on May 1, 2014; DOI: 10.1158/1078-0432.CCR- senescence in human cells (30) implicating for a cell type specificity for requirement of different RB family members in senescence regulation in experimental conditions. Importantly, unlike RB, mutations in p107 or in p130 are rare in human cancer strengthening the important role for RB in tumor suppression among RB protein family (26) . Relevant for the model proposed in this review, a tumor suppressor VHL induced RBdependent senescence in vivo even in the absence of functional p53 (31) . In addition, in human cancer cells, including p53-deficient, reactivation of RB induces senescence phenotype (32) .
The target of RB, E2F1, is a transcription factor which expression is increased in many human cancers (33) . E2F protein family consists of 8 transcription factors (E2F1-8) that are important regulators of cell cycle and cell fate (33) . Even though E2F proteins have overlapping cellular functions, they do differ in their biological roles, for instance, in mammary development and in mammary carcinogenesis (34, 35) . Excellent recent reviews underline specific functions of E2F family members (36, 37) but hereafter, we only concentrate in discussing the role of E2F1 in regulating senescence induction in cancer cells. Related to its role in regulating OIS, several publications have reported downregulation of E2F1 in senescent cells (38, 39) . More importantly, inhibition of E2F1 induces senescence phenotype in cancer and in immortalized cells (17, 33, 40, 41) .
Recent studies have characterized E2F1 target genes relevant for senescence regulation (30, 42) . However, despite of RB proteins, the mechanisms by which E2F1 expression and activity is regulated during senescence regulation have been elusive. Recently, we demonstrated a previously unidentified positive feedback loop between E2F1 and another human oncoprotein CIP2A (43, 44) , and demonstrated that this feedback mechanism promotes tumorigenesis by suppressing senescence induction in breast cancer cell lines, and in HER2-driven breast cancer mouse model (17) . Rescue experiments demonstrated Author Manuscript Published OnlineFirst on May 1, 2014; DOI: 10.1158/1078-0432.CCR- that senescence induction either by p53 activation, or by direct adenoviral overexpression of p21, was fully dependent on capacity of these stimuli to downregulate CIP2A expression (17) . Importantly, CIP2A depletion induced senescence also in breast cancer cells with impaired p53 or Rb function (17) . Moreover, CIP2A was identified as a novel direct target gene for E2F1, explaining how high E2F1 expression in p53 mutant cancer cells drives senescence resistance (17) . In line with these results, also ectopic expression of E2F1 rescues the senescence phenotype in cancer cells (38, 39, 41) and similarly to CIP2A, E2F1 knock-out mouse shows reduced tumorigenesis in MMTV-neu model (17, 35) . In addition to breast cancer, loss of CIP2A has been reported to induce senescent phenotype in gastric cancer and in esophageal squamous cell carcinoma cell lines (45, 46) . Importantly, high CIP2A expression predicts for poor patient survival in more than dozen different human cancer types (44) . Together these results indicate that senescence inhibiting role for CIP2A may be generalized to majority of human cancer types.
The molecular function of CIP2A is to inhibit phosphatase activity of a tumor suppressor phosphatase complex PP2A (44, 47) . Different PP2A complexes regulate serine/threonine phosphorylation of numerous cellular targets implicated in variety of physiological and cellular processes (48) . Although, the role of PP2A is not thus far widely studied in the context of senescence, the emerging evidence does indicate that certain PP2A complexes do promote senescence (49) . Related to role of PP2A in CIP2A-mediated senescence resistance, inhibition of B55α subunit of PP2A was identified to promote stability of E2F1 phosphorylated on serine 364, and to prevent p53-induced downregulation of E2F1 (17) . Together these results indicate that E2F1-CIP2A interplay, involving PP2A (Fig.1) , is an important novel mechanism regulating senescence sensitivity of human cancer cells. Notably, these results does not exclude role for other PP2A and CIP2A targets than E2F1 in the regulation of senescence resistance in cancer cells. 
Clinical-translational advances
Notably, although traditionally considered as apoptosis-inducing agents, many of the currently used chemotherapies most probably exert their therapeutic effect at least partly by senescence induction (50) . For example, significant induction of several senescenceassociated gene expression was detected in prostate tumors after mitoxantrone chemotherapy, and senescence associated-β-galactoside positivity was reported in 41% of breast tumors after neoadjuvant chemotherapy, including cyclophosphamide, doxorubicin and 5-fluorouracil (50) (51) (52) . Based on these and other studies implicating important role for senescence induction in cancer therapy responses, there is an increasing interest to develop pro-senescence cancer therapy strategies (9, 50) . The rationale of driving cancer cells to senescence, rather than apoptosis, is that there is increasing evidence that apoptosis-inducing regimens increases risk for secondary malignancies and mutational evolution of those cancer cells that are spared from apoptosis. However, it should be noted that a recent mouse study indicated that p53-driven senescence induction in tumors might actually protect tumor cells from chemotherapy-induced apoptosis (53) . This can be explained by the fact that senescent cells persist in tumors but are not sensitive to DNAdamaging therapies due to cell cycle arrest (9, 50) . On the other hand, clearance of senescent cells from tumors by innate immune cells has been shown repeatedly (9, 10) .
Altogether it is evident that further studies are needed to clarify the therapeutic potential of pro-senescence strategies separately in each cancer therapy setting.
Harnessing p53 downstream effectors for pro-senescence therapy Several mouse models have indicated that p53 reactivation would be efficient prosenescence therapy strategy (10-13). However, p53 is mutationally inactivated in very large fraction of human cancers, and therefore therapeutic strategies to activate senescence via wild type p53 are unlikely to be efficient in majority of human tumors. To overcome this serious shortcoming, several strategies to reactivate mutated p53 have been developed, and these have been reviewed recently (54) . Importantly, an alternative therapeutic strategy to induce senescence in p53 compromised tumor cells would be to target the mechanisms that promote senescence resistance due to p53 inactivation (Fig.   1 ). Potential such strategies are discussed below.
Senescence induction in cancer cells with compromised p53 function by targeting of p21 and CDKs
As described above, ectopic activation of p21 in p53 mutant cells drives cancer cells effectively to senescence and this is dependent on downregulation of E2F1-CIP2A feedback loop (Fig. 1) (17, (19) (20) (21) . Previously, an inhibitor of guanylate cyclase, LY8583, was demonstrated to increase p21 expression 2-fold and to induce senescence in p53 compromised cancer cells in vitro (19) . Similarly, two chemical compounds inhibiting SCFSkp2 complex, MLN4924 and SZL-P1-41, were recently identified to induce p21 expression followed by senescence in p53-deficient cancer cells in vitro (22, 23) .
MLN4924 and SZL-P1-41 were further shown to significantly inhibit tumor growth of preformed human prostate and lung cancer xenografts (22, 23) , suggesting that Skp2 inhibitors may represent a promising novel class of pro-senescence therapeutics in p53 defective cancer cells.
CDK2 activity is increased in p53 mutant cancers due to p21 inhibition, and either genetic or pharmacological CDK2 inhibition drives senescence in various cell types, including a p53-null human cancer cell line in vitro (24, 25) . Thereby, pharmacological inhibition of CDK2 could be an attractive approach for pro-senescence therapy. Notably, a novel CDK inhibitor, dinaciclib (MK-7965), most potently inhibiting CDK2 and CDK5, is under clinical trials for several cancer types, such as for leukemia, melanoma and breast Author Manuscript Published OnlineFirst on May 1, 2014; DOI: 10.1158/1078-0432.CCR- cancer (55). Dinaciclib does induce apoptosis in tumor cell lines and this could be explained by its activity towards multiple CDK's (56) . However, dinaciclib also reduces phosphorylation of RB in vitro in osteosarcoma cells and in vivo in ovarian cancer cell xenografts (56, 57) and therefore it would be important to validate whether it has senescence-inducing activity in human tumors.
Whereas CDK2 mediates effects of p21 in senescence regulation, CDK4 and CDK6 are important mediators of senescence resistance in cancer cells with inactivated tumor suppressor p16 (Fig.1) (58) . Common between all these CDKs is that they regulate RB and thus they have common target relevant for E2F1 and senescence regulation. In a mouse model, inhibition of CDK4, but not CDK6 or CDK2, induces senescence in Although targeting of E2F1-CIP2A feedback loop appears as an attractive approach for pro-senescence therapy, tools to target selectively this loop are currently limited. Inhibitors targeting E2F family proteins have been generated, however, they are not specific for certain E2F proteins (63, 64) . Interestingly, one of the traditional class of chemotherapies, vinca-alcaloids, inhibits E2F1 expression and induce effectively senescence in human breast cancer cells in vitro (17, 65) . Although the exact mechanism by which vinca-alcaloids inhibit E2F1 remains to be determined, it occurs at the level of mRNA expression and do not involve either p53 or p21 (17) . Vinca-alcaloid vinorelbineinduced senescence was preceded by downregulation of both E2F1 and CIP2A expression, and CIP2A deficiency further enhanced the E2F1 inhibition by vinorelbine (17) . Furthermore, low CIP2A expression in human breast tumors predicted for favorable patient survival in patients treated with vinorelbine (p=0,019) (17) . These results provoke vincaalcaloids as potential clinical inhibitors of E2F1-mediated senescence resistance, and use of CIP2A diagnostics for patient stratification to vinca-alcaloid based pro-senescence therapy.
Notably, CIP2A is one of the most frequently overexpressed oncoproteins across human cancer types, and inhibition of CIP2A by siRNA results in significant reduction of xenograft growth of cervical cancer, head and neck squamous cell carcinoma, breast cancer and bladder urothelial cell carcinoma cells in vivo (44) . 
